Cargando…
Inhibition of LncRNAH19 has the effect of anti‐tumour and enhancing sensitivity to Gefitinib and Chemotherapy in Non‐small‐cell lung cancer in vivo
Lung cancer is one of the most common malignant diseases, which ranked first in both men and women malignancies worldwide. The survival rate of non‐small‐cell lung cancer (NSCLC) has been limited with distant metastasis and shortage of effective chemotherapeutics in recent years. Thus, novel therape...
Autores principales: | Zhou, Yaodong, Zhang, Yixin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214165/ https://www.ncbi.nlm.nih.gov/pubmed/32281297 http://dx.doi.org/10.1111/jcmm.15245 |
Ejemplares similares
-
LncRNAH19 improves insulin resistance in skeletal muscle by regulating heterogeneous nuclear ribonucleoprotein A1
por: Gui, Weiwei, et al.
Publicado: (2020) -
Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas
por: Wang, Xu, et al.
Publicado: (2019) -
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
por: Knight, Louise A, et al.
Publicado: (2004) -
Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013) -
Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)